Rankings
▼
Calendar
TCRX Q1 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TCRX
TScan Therapeutics, Inc.
$69M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+283.6% YoY
Gross Profit
$2M
100.0% margin
Operating Income
-$36M
-1669.7% margin
Net Income
-$34M
-1571.9% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
+226.5%
Cash Flow
Operating Cash Flow
-$38M
Free Cash Flow
-$39M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$333M
Total Liabilities
$123M
Stockholders' Equity
$210M
Cash & Equivalents
$154M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$566,000
+283.6%
Gross Profit
$2M
$566,000
+283.6%
Operating Income
-$36M
-$31M
-15.5%
Net Income
-$34M
-$30M
-13.2%
Revenue Segments
Reportable Segment
$2M
100%
← FY 2025
All Quarters
Q2 2025 →